Skip to main content
Top
Published in: International Journal of Behavioral Medicine 1/2015

01-02-2015

Patients’ Perceptions and Experiences of Familial Hypercholesterolemia, Cascade Genetic Screening and Treatment

Authors: Sarah J. Hardcastle, Ellen Legge, Chris S. Laundy, Sarah J. Egan, Rosemary French, Gerald F. Watts, Martin S. Hagger

Published in: International Journal of Behavioral Medicine | Issue 1/2015

Login to get access

Abstract

Background

Familial hypercholesterolemia (FH) is a serious genetic disorder affecting approximately 1 in every 300 to 500 individuals and is characterised by excessively high low-density lipoprotein (LDL) cholesterol levels, substantially increased risk of early-onset coronary heart disease (CHD) and premature mortality. If FH is untreated, it leads to a greater than 50 % risk of CHD in men by the age of 50 and at least 30 % in women by the age of 60. FH can be diagnosed through genetic screening and effectively managed through pharmacological treatment and lifestyle changes.

Purpose

Familial hypercholesterolemia (FH) is a genetic health condition that increases the risk of cardiovascular disease. Although FH can be effectively managed with appropriate pharmacological and dietary interventions, FH detection rate through genetic screening remains low. The present study explored perceptions and experiences of FH patients (N = 18) involved in a genetic cascade screening programme.

Methods

Face-to-face interviews were conducted to assess patients’ knowledge and understanding of FH, explore factors linked to adherence to health-protective behaviours and examine perceptions of genetic screening.

Results

Thematic analysis of interviews revealed four themes: disease knowledge, severity of FH, lifestyle behavioural change and barriers to cascade screening and treatment. Participants recognised FH as a permanent, genetic condition that increased their risk of CHD and premature mortality. Many participants dismissed the seriousness of FH and the importance of lifestyle changes because they perceived it to be effectively managed through medication. Despite positive attitudes toward screening, many participants reported that relatives were reluctant to attend screening due to their relatives’ ‘fatalistic’ outlook or low motivation. Participants believed that they had insufficient authority or control to persuade family members to attend screening and welcomed greater hospital assistance for contact with relatives.

Conclusions

Findings support the adoption of direct methods of recruitment to cascade screening led by medical professionals, who were perceived as having greater authority. Other implications included the need for clinicians to provide clear information, particularly to those who are asymptomatic, related to the seriousness of FH and the necessity for adherence to medication and lifestyle changes.
Footnotes
1
All quotes are matched to participants by gender (F for female; M for male), followed by age and classification (Index or Relative); for example, a 40-year-old male index case would be M, 40, I.
 
Literature
2.
go back to reference Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on familial hypercholesterolemia. J Clin Lipid. 2011;5(3):S9–S17. doi:10.1016/j.jacl.2011.03.452.CrossRef Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on familial hypercholesterolemia. J Clin Lipid. 2011;5(3):S9–S17. doi:10.​1016/​j.​jacl.​2011.​03.​452.CrossRef
3.
go back to reference Huijgen R, Vissers MN, Kindt I, Trip MD, de Groot E, Kastelein JJ, et al. Assessment of carotid atherosclerosis in normocholesterolemic individuals with proven mutations in the low-density lipoprotein receptor or apolipoprotein B genes. Circ Cardiovasc Genet. 2011;4(4):413–7. doi:10.1161/CIRCGENETICS.110.959239.PubMedCrossRef Huijgen R, Vissers MN, Kindt I, Trip MD, de Groot E, Kastelein JJ, et al. Assessment of carotid atherosclerosis in normocholesterolemic individuals with proven mutations in the low-density lipoprotein receptor or apolipoprotein B genes. Circ Cardiovasc Genet. 2011;4(4):413–7. doi:10.​1161/​CIRCGENETICS.​110.​959239.PubMedCrossRef
5.
go back to reference DeMott K, Nherera L, Shaw EJ, Minhas R, Humphries SE, Kathoria M. Clinical guidelines and evidence review for familial hypercholesterolemia: the identification and management of adults and children with hypercholesterolemia. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2008. DeMott K, Nherera L, Shaw EJ, Minhas R, Humphries SE, Kathoria M. Clinical guidelines and evidence review for familial hypercholesterolemia: the identification and management of adults and children with hypercholesterolemia. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2008.
7.
go back to reference Smilde TJ, Van Wissen S, Wollersheim H, Tri MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerotic progression in familial hypercholesterolemia: a prospective, double-blind randomised trial. Lancet. 2001;357:577–8. doi:10.1016/S0140-6736(00)04053-8.PubMedCrossRef Smilde TJ, Van Wissen S, Wollersheim H, Tri MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerotic progression in familial hypercholesterolemia: a prospective, double-blind randomised trial. Lancet. 2001;357:577–8. doi:10.​1016/​S0140-6736(00)04053-8.PubMedCrossRef
8.
go back to reference Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2000;4(1):1–123. doi:10.3310/hta4290.PubMed Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2000;4(1):1–123. doi:10.​3310/​hta4290.PubMed
10.
11.
go back to reference Hallowell N, Jenkins N, Douglas M, Walker S, Finne R, Porteous M, et al. Patients’ experiences and views of cascade screening for familial hypercholesterolemia (FH): a qualitative study. J Com Genet. 2011;2(4):249–57. doi:10.1007/s12687-011-0064-y.CrossRef Hallowell N, Jenkins N, Douglas M, Walker S, Finne R, Porteous M, et al. Patients’ experiences and views of cascade screening for familial hypercholesterolemia (FH): a qualitative study. J Com Genet. 2011;2(4):249–57. doi:10.​1007/​s12687-011-0064-y.CrossRef
14.
go back to reference Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolemia. Br Med J. 2002;324(7349):1303. doi:10.1136/bmj.324.7349.1303.CrossRef Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolemia. Br Med J. 2002;324(7349):1303. doi:10.​1136/​bmj.​324.​7349.​1303.CrossRef
15.
go back to reference Huijgen R, Versmissen J, Oosterveer DM, Kindt I, Sijbrands EJG, Kastelein JJP. Efficacy of 15 years of genetic cascade screening for familial hypercholesterolemia in the Netherlands in prevention of coronary artery disease. Atheroscler Suppl. 2010;11(2):14. doi:10.1016/S1567-5688(10)70066-0.CrossRef Huijgen R, Versmissen J, Oosterveer DM, Kindt I, Sijbrands EJG, Kastelein JJP. Efficacy of 15 years of genetic cascade screening for familial hypercholesterolemia in the Netherlands in prevention of coronary artery disease. Atheroscler Suppl. 2010;11(2):14. doi:10.​1016/​S1567-5688(10)70066-0.CrossRef
17.
go back to reference Hadfield SG, Horara S, Starr BJ, Yazdgerdi S, Marks D, Bhatnagar D, et al. Family tracing to identify patients with familial hypercholesterolemia: the second audit of the Department of Health Familial Hypercholesterolemia Cascade Testing Project. Ann Clin Biochem. 2009;46:24–32. doi:10.1258/acb.2008.008094.PubMedCrossRef Hadfield SG, Horara S, Starr BJ, Yazdgerdi S, Marks D, Bhatnagar D, et al. Family tracing to identify patients with familial hypercholesterolemia: the second audit of the Department of Health Familial Hypercholesterolemia Cascade Testing Project. Ann Clin Biochem. 2009;46:24–32. doi:10.​1258/​acb.​2008.​008094.PubMedCrossRef
18.
go back to reference Horstman K, Smand C. Detecting familial hypercholesterolemia: escaping the family history? In: De Vries G, Horstman K, editors. Genetics from the laboratory to society: Societal learning as an alternative to regulation. Basingstoke, UK: Palgrave Macmillan; 2008. p. 90–117. Horstman K, Smand C. Detecting familial hypercholesterolemia: escaping the family history? In: De Vries G, Horstman K, editors. Genetics from the laboratory to society: Societal learning as an alternative to regulation. Basingstoke, UK: Palgrave Macmillan; 2008. p. 90–117.
19.
go back to reference van Maarle MC, Stouthard MEA, Marang-van de Mheen PJ, Klazinga NS, Bonsel GJ. How disturbing is it to be approached for a genetic cascade screening programme for familial hypercholesterolaemia? Psychological impact and screenees’ views. Community Genet. 2001;4(4):244–52.PubMedCrossRef van Maarle MC, Stouthard MEA, Marang-van de Mheen PJ, Klazinga NS, Bonsel GJ. How disturbing is it to be approached for a genetic cascade screening programme for familial hypercholesterolaemia? Psychological impact and screenees’ views. Community Genet. 2001;4(4):244–52.PubMedCrossRef
21.
go back to reference Senior V, Marteau TM, Peters TJ. Will genetic testing for predisposition for-disease result in fatalism? A qualitative study of parents responses to neonatal screening for familial hypercholesterolaemia. Soc Sci Med. 1999;48(12):1857–60. doi:10.1016/s0277-9536(99)00099-4.PubMedCrossRef Senior V, Marteau TM, Peters TJ. Will genetic testing for predisposition for-disease result in fatalism? A qualitative study of parents responses to neonatal screening for familial hypercholesterolaemia. Soc Sci Med. 1999;48(12):1857–60. doi:10.​1016/​s0277-9536(99)00099-4.PubMedCrossRef
23.
go back to reference Claassen L, Henneman L, Kindt I, Marteau TM, Timmermans DR. Perceived risk and representations of cardiovascular disease and preventive behaviour in people diagnosed with familial hypercholesterolemia. J Health Psychol. 2010;15:33–43. doi:10.1177/1359105309345170.PubMedCrossRef Claassen L, Henneman L, Kindt I, Marteau TM, Timmermans DR. Perceived risk and representations of cardiovascular disease and preventive behaviour in people diagnosed with familial hypercholesterolemia. J Health Psychol. 2010;15:33–43. doi:10.​1177/​1359105309345170​.PubMedCrossRef
24.
27.
go back to reference Jenkins N, Lawton J, Douglas M, Walker S, Finnie A, Porteous M, et al. How do index patients participating in genetic screening programmes for familial hypercholesterolemia (FH) interpret their DNA results? A UK-based qualitative interview study. Patient Educ Couns. 2013;90(3):372–7. doi:10.1016/j.pec.2011.09.002.PubMedCrossRef Jenkins N, Lawton J, Douglas M, Walker S, Finnie A, Porteous M, et al. How do index patients participating in genetic screening programmes for familial hypercholesterolemia (FH) interpret their DNA results? A UK-based qualitative interview study. Patient Educ Couns. 2013;90(3):372–7. doi:10.​1016/​j.​pec.​2011.​09.​002.PubMedCrossRef
32.
go back to reference Marteau T, Senior V, Humphries SE, Bobrow M, Cranston T, Crook MA, et al. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am J Med Genet A. 2004;128A(3):285–93. doi:10.1002/ajmg.a.30102.PubMedCrossRef Marteau T, Senior V, Humphries SE, Bobrow M, Cranston T, Crook MA, et al. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am J Med Genet A. 2004;128A(3):285–93. doi:10.​1002/​ajmg.​a.​30102.PubMedCrossRef
34.
go back to reference Hollman G, Olsson AG, Ek AC. Disease knowledge and adherence to treatment in patients with familial hypercholesterolemia. J Cardiovasc Nurs. 2006;21(2):103–8.PubMedCrossRef Hollman G, Olsson AG, Ek AC. Disease knowledge and adherence to treatment in patients with familial hypercholesterolemia. J Cardiovasc Nurs. 2006;21(2):103–8.PubMedCrossRef
35.
go back to reference Hagger MS, Chatzisarantis NLD. Never the twain shall meet? Quantitative psychological researchers’ perspectives on qualitative research. Qual Res Sport Exerc Health. 2011;3:266–77. Hagger MS, Chatzisarantis NLD. Never the twain shall meet? Quantitative psychological researchers’ perspectives on qualitative research. Qual Res Sport Exerc Health. 2011;3:266–77.
Metadata
Title
Patients’ Perceptions and Experiences of Familial Hypercholesterolemia, Cascade Genetic Screening and Treatment
Authors
Sarah J. Hardcastle
Ellen Legge
Chris S. Laundy
Sarah J. Egan
Rosemary French
Gerald F. Watts
Martin S. Hagger
Publication date
01-02-2015
Publisher
Springer US
Published in
International Journal of Behavioral Medicine / Issue 1/2015
Print ISSN: 1070-5503
Electronic ISSN: 1532-7558
DOI
https://doi.org/10.1007/s12529-014-9402-x

Other articles of this Issue 1/2015

International Journal of Behavioral Medicine 1/2015 Go to the issue